Navigation Links
FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
Date:7/20/2009

essure patients. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7) recommends that physicians consider starting their high blood pressure patients with two treatment agents, one of which should be a diuretic, if blood pressure is >20/10 mmHg above goal. The use of multiple medications may help patients achieve blood pressure goals in a more timely fashion.

"We are very pleased the FDA recognizes the benefit of Tekturna HCT for the first-line treatment of patients with moderately high blood pressure," said Trevor Mundel, MD, Global Head of Development at Novartis Pharma AG. "Novartis is committed to supporting the research and development of effective treatments for high blood pressure that will help patients reach their blood pressure treatment goals."

Tekturna, a direct renin inhibitor, is the only drug that works by directly targeting renin and decreasing the activity of the RAAS. Renin is an enzyme produced by the kidneys that starts a process that makes blood vessels narrow and, when inappropriately activated, may lead to high blood pressure. Tekturna reduces renin activity and helps blood vessels relax and widen so blood pressure is lowered. Diuretics work to lower blood pressure by removing excess water and salt from the body.

Tekturna was approved in the US in 2007 as the first direct renin inhibitor. In 2008, Tekturna HCT was approved in the US for second-line treatment of high blood pressure. The long-term potential of Tekturna is being studied in an extensive clinical program, including outcomes trials, known as ASPIRE HIGHER.

Tekturna HCT is available in four strengths as tablets containing aliskiren and hydrochlorothiazide: 150 mg/12.5 mg tablets, 150 mg/25 mg tablets, 300 mg/12.5 mg tablets and 300 mg/25 mg tablets.

Study details

The FDA
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... YORK , Sept. 17, 2014 ... 2020 Summary GlobalData,s ... 2020", provides key market data on the Brazil ... millions of US dollars, volume (in units) and ... - Female Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) ...
(Date:9/17/2014)... , Sept. 17, 2014 The ... the last decade due to the recession, ... and technological advancements. This BCC Research report ... segments of the ambulance and emergency medical ... blood and hemorrhage control devices, equipment used ...
(Date:9/17/2014)... , Sept. 17, 2014  Dr. Stephen ... the White House today for National Recovery Month, stars ... consumer advocates released today. Consumer advocates were also joined ... who spoke out after losing her fiancée because of ... the doctor had a history of crack cocaine abuse. ...
Breaking Medicine Technology:Brazil Gynecological Devices Market Outlook to 2020 2Brazil Gynecological Devices Market Outlook to 2020 3Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3
... MOUNTAIN VIEW, Calif., Jan. 26, 2012 Omnicell, Inc. (NASDAQ: ... healthcare facilities, today announced results for its fourth quarter and ... Revenue for the fourth quarter of 2011 was $62.9 million, ... 2010 and down $1.5 million or 2.3% from the third ...
... 2012 Amgen (NASDAQ: AMGN ) reported total ... to $3,973 million versus $3,841 million in the fourth quarter ... 4 percent to $15,582 million from $15,053 million in 2010. ... the fourth quarter of 2011, an increase of 3 percent ...
Cached Medicine Technology:Omnicell Announces Fourth Quarter and Full Year 2011 Results 2Omnicell Announces Fourth Quarter and Full Year 2011 Results 3Omnicell Announces Fourth Quarter and Full Year 2011 Results 4Omnicell Announces Fourth Quarter and Full Year 2011 Results 5Omnicell Announces Fourth Quarter and Full Year 2011 Results 6Omnicell Announces Fourth Quarter and Full Year 2011 Results 7Omnicell Announces Fourth Quarter and Full Year 2011 Results 8Omnicell Announces Fourth Quarter and Full Year 2011 Results 9Omnicell Announces Fourth Quarter and Full Year 2011 Results 10Omnicell Announces Fourth Quarter and Full Year 2011 Results 11Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 2Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 3Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 4Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 5Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 6Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 7Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 8Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 9Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 10Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 11Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 12Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 13Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 14Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 15Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 16Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 17Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 18Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 19
(Date:9/17/2014)... Historically, spaceflight has been reserved for the very ... meet the highest physical and psychological standards to ... the advent of commercial spaceflight, average people can ... has had very little information about what medical ... in the spaceflight environment, as most medical conditions ...
(Date:9/17/2014)... People who struggle to distinguish between a business strategy and ... get the answer by reading Per Wickstrom’s latest blog post. ... business plan and a business strategy are both strategic – ... way I view it is that a business plan is ... two.” , According to the blog post, a business ...
(Date:9/17/2014)... manipulation these sound like the ideas of ... are components of an exciting new approach to ... models of metastatic prostate cancer, scientists at Virginia ... Molecular Medicine and Johns Hopkins Medical Institutions have ... that could revolutionize doctors, ability to see tumors ...
(Date:9/17/2014)... N.J. (PRWEB) September 17, 2014 ... advanced delivery technologies and development solutions for drugs, ... launch of OptiPact™, an integrated service and technology ... compaction, and provided from the company’s 450,000 sq. ... describes Catalent’s ability to integrate optimal formulation, development, ...
(Date:9/17/2014)... WEDNESDAY, Sept. 17, 2014 (HealthDay News) -- Positive messages ... some people kick the habit, a new study suggests. ... responded better to "loss-framed" messages about the harmful effects ... quit whenever they want benefit more from "gain-framed," or ... The researchers concluded that using a mix of ...
Breaking Medicine News(10 mins):Health News:Space: The final frontier… open to the public 2Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:New OptiPact™ Technology Introduced by Catalent 2Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2
... University,s Physical Activity and Public Health Laboratory, active commuting ... can be an easy, effective and efficient way to ... Wittman, a K-State senior in kinesiology, Olathe, worked with ... of kinesiology, on the active commuting research. The project ...
... April 13 Mylan Inc. (Nasdaq: MYL ... banker,Andrew G. Cuneo as vice president of Global Business ... and strategic,efforts in close alignment with the company,s executive ... Chairman and CEO Robert J. Coury said: "Drew brings ...
... 13 Lionbridge,Technologies, Inc. (Nasdaq: ... testing,and development services today announced an alliance ... Enterprise Content Management (ECM) software,designed to ensure ... management solutions for pharmaceutical companies and other,organizations. ...
... could one day quickly detect if treatment is working, study ... technique that can detect subtle changes in cancer cells contained ... tissue may one day be used by doctors to better ... , "Currently, we don,t know what,s going on in a ...
... Though a high-fiber diet has long been considered good ... Medical College of Georgia researchers have discovered a reason ... Researchers report in the April issue of Cancer ... butyrate, a metabolite produced by fiber-eating bacteria in the ...
... 15th, there will be a,Capitol Hill briefing called ... and Mental Illness." Author and award winning ... HELP USA,Lamp Community, the National Alliance on Mental ... H.O.M.E. have join forces to host this,important briefing. ...
Cached Medicine News:Health News:Survey research looks at attitudes, obstacles to walking and biking to work 2Health News:Survey research looks at attitudes, obstacles to walking and biking to work 3Health News:Andrew G. Cuneo Joins Mylan as Vice President of Global Business Development 2Health News:Lionbridge Announces Partnership with Open Text to Streamline Regulatory Compliance Solutions for Pharmaceutical Companies 2Health News:A Drop of Blood May Help Assess Cancer Therapy 2Health News:Colon cancer shuts down receptor that could shut it down 2Health News:Colon cancer shuts down receptor that could shut it down 3Health News:Capitol Hill Briefing Scheduled for April 15th About Homelessness and Mental Illness 2Health News:Capitol Hill Briefing Scheduled for April 15th About Homelessness and Mental Illness 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: